Background/Aims: Autophagy is a well-known pathway to "clean" the misfolded mutant huntingtin protein (mHtt), which plays a considerable role in polyglutamine diseases. To date, there have been few studies of the choice of anesthetic during surgery in patients with polyglutamine diseases and evaluation of the effects and underlying mechanisms of anesthetics in these patients. Methods: GFP-Htt (Q74)-PC12 cells, which stably express green fluorescent protein-tagged Htt protein containing 74 glutamine repeating units, were used throughout this study. Cells were treated with 15 μM midazolam and 100 mM trehalose (positive control), and the induction of autophagy and autophagic degradation were assessed by detecting changes in autophagy-related proteins and substrates, and cell viability was assessed using the MTT assay. Overexpression of cathepsin D by plasmid transfection was used to restore midazolamimpaired autophagic degradation. Results: Midazolam increased intracellular mHtt levels in a time-and dose-dependent manner. Additionally, enhancing or blocking autophagic flux by trehalose or chloroquine could decrease or increase midazolam-induced mHtt elevation, respectively. Midazolam induced autophagy in the mTOR-dependent signaling pathway, but autophagic degradation was impaired, with a continuous rise in p62 and LC3 II levels and decrease in cathepsin D. However, overexpression of cathepsin D reversed the effects of midazolam. Midazolam led to a 20% decrease in GFP-Htt (Q74)-PC12 cell viability, which could be abrogated by overexpression of cathepsin D. Conclusions: Midazolam increased mHtt levels and decreased Htt (Q74)-PC12 cell viability via impairment of autophagic degradation, which could be restored by overexpression of cathepsin D.
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Introduction
Increasing evidence has demonstrated that accumulation and aggregation of misfolded proteins cause neurodegenerative disease, such as Alzheimer's disease (AD), Parkinson's disease (PD), and polyglutamine diseases [1, 2] . Polyglutamine diseases, including Huntington's disease (HD), dentatorubral-pallidoluysian atrophy, spinal and bulbal muscular atrophy, several types of spinocerebellar ataxias, and Huntington's disease-like 2 [3] , are the result of the aggregation of misfolded mutant huntingtin (mHtt) proteins exhibiting more than 35 glutamine repeating units in diseased neurons [4, 5] . These mHtt proteins usually promote neuronal death when in the form of toxic multimeric complexes [6, 7] , although normal huntingtin (Htt) protein is important for neuronal function [8] . Among the polyglutamine diseases, HD is the most prevalent.
There are two main mechanistic pathways for proteolysis in eukaryotes, the ubiquitinproteasome system (UPS) and autophagy-lysosomal pathway (ALP) [9, 10] . Short-lived intracellular proteins are mainly removed by the UPS, whereas most long-lived proteins, misfolded proteins, protein aggregates, and damaged organelles are degraded by the ALP [11] . Aggregated mHtt proteins are inefficiently degraded by the proteasome due to their size; hence, they can be targeted for degradation by autophagy [3] . Autophagy is a lysosomebased evolutionarily conserved and dynamic intracellular process, in which cytoplasmic constituents are engulfed by autophagosomes and delivered to lysosomes for degradation [12] . Impaired autophagy can lead to abnormal protein aggregation and result in severe disease, such as AD, PD, and polyglutamine diseases [3, 13, 14] . However, upregulating autophagy by some small molecules and nanomaterials, such as trehalose, rapamycin, lithium, and europium hydroxide nanorods, may be useful for the treatment of these diseases [15] [16] [17] [18] .
To date, the choice of anesthetic during surgery in patients with polyglutamine diseases and evaluation of the effects and underlying mechanisms in these patients have rarely been reported [19] . Midazolam is a commonly used intravenous anesthetic for sedation and balanced general anesthesia during surgery, and it has been reported to be used in HD patients [20, 21] . In the present study, we found that midazolam increased the accumulation of mHtt proteins in vitro, which was caused by the dysfunction of autopahgic degradation. However, through overexpression of cathepsin D, midazolam-impaired autophagic degradation was restored, and mHtt was degraded to relatively low levels, resulting in increased cell survival. Here, our results revealed the risk of accelerating the pathogenesis of polyglutamine diseases by midazolam and suggested that cathepsin D might be a candidate target for reduction of midazolam-dependent neurotoxicity.
Materials and Methods

Antibodies and agents
Anti-LC3 antibody (1:2000, NB100-2220) was purchased from Novus Biologicals (Littleton, CO); nti-SQSTM1/p62 antibody (1:2000, ab56416) was purchased from Abcam (Cambridge, UK); anti-RS6KB antibody (anti-p70 S6 kinase, 1:1000, 9202), anti-phosphorylated RS6KB antibody (anti-phospho-p70 S6kinase, 1:1000, 9205), anti-mTOR antibody (1:1000, 2983), and anti-p-mTOR antibody (1:1000, 2971) were purchased from Cell Signaling Technology (Danvers, MAA); nti-GAPDH antibody (1:10, 000, AB9132) was purchased from Merck Millipore (Darmstadt, Germany); anti-green fluorescent protein (GFP) antibody 
Cell culture
Cells were cultured at 37°C with 5% CO 2 in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS). PC12 stable cells were transfected with GFP-tagged Htt (Q74) expression vectors using Lipofectamine 2000 and selected in medium containing 0.6 mg/ml G418.
Cell viability assay
Cells were seeded in 96-well plates (10 4 /well) and cultured at 37°C with 5% CO 2 . Wild-type cells or cathepsin D-overexpressed cells were treated with 15 μM midazolam for 48 h. Then, 10 μl MTT (5 mg/ml) was added to each well and incubated at 37°C for 4 h. After removing the medium, formazan crystals were dissolved in 100 μl DMSO, and the absorbance was measured at 570 nm using a microplate reader (Nano Quant, Tecan, Männedorf, Switzerland).
Immunofluorescence
Cells were fixed using 4% paraformaldehyde for 10 min, permeabilized with 0.1% Triton X-100 for 10 min, and blocked with 1% FBS for 1 h. Cells were incubated with the primary antibody overnight at 4°C and labeled with the secondary antibody at 37°C for 1 h. Images were acquired using an LSM 710 confocal microscope (Carl Zeiss AG, Oberkochen Germany.
Western blotting
Cells were lysed with sample buffer and boiled for 10 min. Proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis and were transferred onto nitrocellulose membranes. The membranes were incubated with the primary antibody at 4°C overnight and the second antibody for 1 h at 37°C. Membranes were incubated with the ECL kit and visualized using a chemiluminescence instrument (ImageQuant LAS 4000, GE Healthcare, Little Chalfont, UK).
Statistical analysis
All data were expressed as the mean ± SEM and analyzed by analysis of variance or two-tailed Student's t-tests. * P < 0.05, ** P < 0.01, and *** P < 0.001 were considered statistically significant.
Results
Midazolam induced GFP-Htt (Q74) accumulation
GFP-Htt (Q74)-PC12 cells were generated from a PC12 cell line which stably expressed GFP-tagged Htt protein containing 74 glutamine repeating units. In these cells, GFP-Htt (Q74) protein was observed as bright punctate dots [22] , indicating the formation of aggregates. As shown in Fig. 1a-d , midazolam increased the percentage of cells containing GFP-Htt (Q74) aggregates in a time-and dose-dependent manner. Further, the cytoplasmic mHtt protein levels were significantly increased following midazolam treatment at doses greater than 5 μM (Fig. 1e, g ). Additionally, 15 μM midazolam treatment significantly increased GFP-Htt (Q74) levels after 36 h (Fig. 1f, h ). Collectively, our results showed that midazolam could induce mHtt accumulation in GFP-Htt (Q74)-PC12 cells.
Role of autophagy in midazolam-induced GFP-Htt (Q74) accumulation
As autophagy is the main pathway for mHtt protein degradation, we tested the role of autophagy in midazolam-treated cells. Trehalose and CQ are commonly used as an autophagy inducer and blocker, respectively [18, 23] . Trehalose significantly attenuated the elevation of GFP-Htt (Q74) puncta following midazolam treatment, but CQ had the opposite effect (Fig.  2a, b) . Furthermore, western blotting results showed that the level of GFP-Htt (Q74) was decreased following treatment with trehalose plus midazolam, compared with midazolam alone (Fig. 2c, e) ; by contrast, saturated CQ further increased GFP-Htt (Q74) accumulation Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry (Fig. 2c, e ). These data demonstrate the important role of autophagy in midazolam-induced mHtt protein accumulation. UPS, another important pathway for proteolysis in eukaryotes, could be inhibited by MG132 [22] . However, there was no significant change in the percentage of GFP-Htt (Q74) puncta or in GFP-Htt (Q74) protein levels between midazolam-and MG132 plus midazolamtreated cells (Fig. 2d, f) . Taken together, these results suggest that ALP, rather than UPS, is involved in midazolam-elicited GFP-Htt (Q74) accumulation.
Midazolam induced autophagy in the mTOR-dependent signaling pathway
Next, autophagy induction in midazolam-treated cells was determined. During the autophagy process, the autophagy marker protein LC3 is cleaved from LC3 I into the lower molecular weight LC3 II and aggregates on autophagosome membranes [24] . Thus, using immunofluorescence staining, we found that midazolam and its positive control trehalose elicited large numbers of LC3 puncta (Fig. 3a) , indicating the formation of autophagosomes. Additionally, LC3 II levels in the midazolam-and trehalose-treated cells were increased (Fig.  3b) , further confirming the formation of autophagosomes. Autophagosomes fuse with several lysosomes to form autolysosomes, in which the autophagic contents are degraded. LAMP1, a lysosomal membrane protein, and structures with overlapping immunofluorescence staining for LAMP1 and LC3 were considered autolysosomes [25, 26] . As shown in Fig. 3c, LC3 and LAMP1 signals clearly overlapped, suggesting the formation of autolysosomes. mTOR is a key molecule in the autophagy pathway, and protein S6 kinase (p70S6K) is its substrate [27, 28] . Western blotting results showed that midazolam decreased the phosphorylation of mTOR and p70S6K (Fig. 3d) . Together, these results demonstrated that midazolam induced autophagy in the mTOR-dependent signaling pathway in PC12 cells.
Midazolam impaired autophagic degradation
Accumulation of GFP-Htt (Q74) and enlarged autolysosomes (Fig. 3c) suggested the blockade of autophagic flux [23, 29] ; thus, we measured autophagic degradation. The effect of sequestosome 1 (SQSTM1/p62), a protein substrate that is selectively incorporated during the formation of autophagosomes and degraded by autophagy, was investigated first [30] . p62 levels were decreased with time in the positive control trehalose-treated cells, but significantly increased by midazolam (Fig. 4a, b) , indicating a lack of degradation of p62. Although LC3 II is increased during the induction of autophagy, it is degraded and decreased for recycling at the late stage of autophagy [24] . However, midazolam treatment continued to increase LC3 II levels, in contrast to the positive control group (Fig. 4a, c) . Next, levels of the lysosomal protease cathepsin D were measured. As shown in Fig. 4a and d , both the precursor and mature forms of cathepsin D were decreased after midazolam treatment for 24 h, but there were no obvious changes in trehalose-treated cells, suggesting the disrupted function of autolysosomes. 
Overexpression of cathepsin D enhanced GFP-Htt (Q74) degradation and promoted cell survival
Through overexpression of cathepsin D (Fig. 5a) , we aimed to restore autophagic degradation. Indeed, the levels of p62 (Fig. 5a, b) and Htt (Q74) (Fig. 5a, c) were decreased during midazolam treatment in cathepsin D-overexpressed cells, suggesting normal autopahgic degradation. This further illustrates the important role of autophagy in polyglutamine diseases.
It has been well documented that aggregated mHtt protein is toxic to cells [31] , and we found that midazolam led to a 20% decrease in GFP-Htt (Q74)-PC12 cell viability (Fig. 5d) , but midazolam was not toxic in wild-type PC12 cells (data not show). Moreover, reduction of mHtt protein through cathepsin D overexpression could significantly restore cell viability (Fig. 5d) , revealing that the toxicity of midazolam in GFP-Htt (Q74)-PC12 cells resulted from aggregated mHtt. The proposed mechanism underlying the effect of midazolam on mHtt accumulatin and cell toxicity is shown schematically in Fig. 6 .
Discussion
In this study, through fluorescence microscopy observations and western blotting results, we found that the commonly used intravenous anesthetic midazolam could increase intracellular mHtt, but other intravenous anesthetics, such as propofol and etomidate, had no effect (data not show). However, the elevation of mHtt may promote the pathological development of polyglutamine diseases, such as HD, as aggregated mHtt is toxic to cells Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry [3] . Indeed, our MTT results showed that GFP-Htt (Q74)-PC12 cells are more vulnerable to midazolam compared with wild-type cells (data not show). Thus, our study revealed for the first time that an intravenous anesthetic increased the risk of accelerating the pathogenesis of polyglutamine diseases, indicating that midazolam may not be the anesthetic of choice for use in patients with these diseases. The UPS and ALP pathways are two main mechanistic pathways for proteolysis in eukaryotes. In the present study, autophagy, an important biological degradative process, was shown to be the main pathway for mHtt degradation in midazolam-treated cells, as enhancing or blocking autophagic flux by trehalose or CQ could decrease or increase midazolam-induced elevation of mHtt, respectively. Surprisingly, we found that midazolam could also induce autophagy in the mTOR-dependent signaling pathway, which should have decreased the intracellular mHtt levels. Further investigation showed that midazolam impaired autophagic degradation by inducing considerable non-functional autolysosome formation. Thus, accumulation of mHtt with autophagy induction in midazolam-treated cells is reasonable.
Autophagic degradation occurs in the autolysosome and is dependent on lysosomal proteases. However, in this study, cathepsins D, an important aspartate protease, was found to be decreased in midazolam-treated cells. Loss of cathepsin D in processing damaged or aggregated proteins has been demonstrated in neuronal cell death and neurological disorders [31] [32] [33] [34] , consistent with our results. Furthermore, mHtt degradation and cell viability were enhanced though overexpression of cathepsin D, suggesting that cathepsin D may be a target for reduction of midazolam-induced neurotoxicity and treatment of polyglutamine diseases.
This study was conducted in transgenic cells in vitro, which could be used for the simultaneous high-throughput detection of toxicity of various anesthetics in different diseases [35, 36] . Furthermore, this model is time-efficient and economical for intensive study of molecular mechanisms and for investigating drug targets for various disease [37] . However, in vitro cell experiments are unilateral, and they cannot completely simulate the pathological process in vivo. Thus, the effect and mechanism of action of midazolam in polyglutamine diseases should be further investigated in vivo.
In summary, midazolam-induced dysfunctional autophagy contributed to the accumulation of mHtt in PC12-Q74 cells, and the aggregated mHtt may responsible for the toxicity of midazolam. Cathepsin D may be a candidate target for reduction of this neurotoxicity, and our results revealed the risk of accelerating the pathogenesis of HD or polyglutamine diseases by midazolam.
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